Cynata Therapeutics Ltd
Research Cynata Therapeutics Ltd (CYP) on Bullrun: market cap AUD 2.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCYP
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 2.92M
- Financial periodFY2025
- Net income-AUD 9.39M
- Free cash flow-AUD 8.77M
Valuation Snapshot
latest market cap is AUD 2.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 9.39M | -AUD 8.77M | n/a | -0.05 | AUD 5.05M | n/a | AUD 5.98M |
| FY2024 | n/a | -AUD 9.74M | -AUD 9.96M | n/a | -0.05 | AUD 6.21M | n/a | AUD 7.22M |
| FY2023 | n/a | -AUD 14.28M | -AUD 14.28M | n/a | -0.1 | AUD 16.17M | n/a | AUD 16.73M |
| FY2022 | n/a | -AUD 5.45M | -AUD 3.30M | n/a | -0.04 | AUD 23.80M | n/a | AUD 23.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 2.92M | n/a | n/a | n/a |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cynata Therapeutics Ltd's market cap?
Cynata Therapeutics Ltd's market capitalization is AUD 2.92M.
What does Cynata Therapeutics Ltd do?
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.